|
1
|
Deorah S, Lynch CF, Sibenaller ZA and
Ryken TC: Trends in brain cancer incidence and survival in the
United States: Surveillance, Epidemiology, and End Results Program,
1973 to 2001. Neurosurg Focus. 20:E12006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
von Deimling A, von Ammon K, Schoenfeld D,
Wiestler OD, Seizinger BR and Louis DN: Subsets of glioblastoma
multiforme defined by molecular genetic analysis. Brain Pathol.
3:19–26. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
DeAngelis LM: Brain tumors. N Engl J Med.
344:114–123. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moon SY and Zheng Y: Rho GTPase-activating
proteins in cell regulation. Trends Cell Biol. 13:13–22. 2003.
View Article : Google Scholar
|
|
5
|
Yamazaki D, Kurisu S and Takenawa T:
Regulation of cancer cell motility through actin reorganization.
Cancer Sci. 96:379–386. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
El-Sibai M, Pertz O, Pang H, Yip SC,
Lorenz M, Symons M, Condeelis JS, Hahn KM and Backer JM:
RhoA/ROCK-mediated switching between Cdc42- and Rac1-dependent
protrusion in MTLn3 carcinoma cells. Exp Cell Res. 314:1540–1552.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ananthakrishnan R and Ehrlicher A: The
forces behind cell movement. Int J Biol Sci. 3:303–317. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vega FM, Fruhwirth G, Ng T and Ridley AJ:
RhoA and RhoC have distinct roles in migration and invasion by
acting through different targets. J Cell Biol. 193:655–665. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
El-Sibai M and Backer JM: Phospholipase C
γ negatively regulates Rac/Cdc42 activation in antigen-stimulated
mast cells. Eur J Immunol. 37:261–270. 2007. View Article : Google Scholar
|
|
10
|
Moorman JP, Luu D, Wickham J, Bobak DA and
Hahn CS: A balance of signaling by Rho family small GTPases RhoA,
Rac1 and Cdc42 coordinates cytoskeletal morphology but not cell
survival. Oncogene. 18:47–57. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ridley AJ: RhoA, RhoB and RhoC have
different roles in cancer cell migration. J Microsc. 251:242–249.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Buchsbaum RJ: Rho activation at a glance.
J Cell Sci. 120:1149–1152. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
O'Connor K and Chen M: Dynamic functions
of RhoA in tumor cell migration and invasion. Small GTPases.
4:141–147. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ridley AJ: Life at the leading edge. Cell.
145:1012–1022. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ellenbroek SI and Collard JG: Rho GTPases:
Functions and association with cancer. Clin Exp Metastasis.
24:657–672. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vega FM and Ridley AJ: Rho GTPases in
cancer cell biology. FEBS Lett. 582:2093–2101. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Boettner B and Van Aelst L: The role of
Rho GTPases in disease development. Gene. 286:155–174. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Khalil BD, Hanna S, Saykali BA, El-Sitt S,
Nasrallah A, Marston D, El-Sabban M, Hahn KM, Symons M and El-Sibai
M: The regulation of RhoA at focal adhesions by StarD13 is
important for astrocytoma cell motility. Exp Cell Res. 321:109–122.
2014. View Article : Google Scholar
|
|
19
|
Lauffenburger DA and Horwitz AF: Cell
migration: A physically integrated molecular process. Cell.
84:359–369. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bermudez O, Pagès G and Gimond C: The
dual-specificity MAP kinase phosphatases: Critical roles in
development and cancer. Am J Physiol Cell Physiol. 299:C189–C202.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vial E, Sahai E and Marshall CJ: ERK-MAPK
signaling coordinately regulates activity of Rac1 and RhoA for
tumor cell motility. Cancer Cell. 4:67–79. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sebolt-Leopold JS, Dudley DT, Herrera R,
Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges
A, Przybranowski S, et al: Blockade of the MAP kinase pathway
suppresses growth of colon tumors in vivo. Nat Med. 5:810–816.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Krueger JS, Keshamouni VG, Atanaskova N
and Reddy KB: Temporal and quantitative regulation of
mitogen-activated protein kinase (MAPK) modulates cell motility and
invasion. Oncogene. 20:4209–4218. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zohrabian VM, Forzani B, Chau Z, Murali R
and Jhanwar-Uniyal M: Rho/ROCK and MAPK signaling pathways are
involved in glioblastoma cell migration and proliferation.
Anticancer Res. 29:119–123. 2009.PubMed/NCBI
|
|
25
|
Bradley KA, Mogridge J, Mourez M, Collier
RJ and Young JA: Identification of the cellular receptor for
anthrax toxin. Nature. 414:225–229. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Scobie HM, Rainey GJ, Bradley KA and Young
JA: Human capillary morphogenesis protein 2 functions as an anthrax
toxin receptor. Proc Natl Acad Sci USA. 100:5170–5174. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Abi-Habib RJ, Urieto JO, Liu S, Leppla SH,
Duesbery NS and Frankel AE: BRAF status and mitogen-activated
protein/extracellular signal-regulated kinase kinase 1/2 activity
indicate sensitivity of melanoma cells to anthrax lethal toxin. Mol
Cancer Ther. 4:1303–1310. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Abrami L, Liu S, Cosson P, Leppla SH and
van der Goot FG: Anthrax toxin triggers endocytosis of its receptor
via a lipid raft-mediated clathrin-dependent process. J Cell Biol.
160:321–328. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Melnyk RA and Collier RJ: A loop network
within the anthrax toxin pore positions the phenylalanine clamp in
an active conformation. Proc Natl Acad Sci USA. 103:9802–9807.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang D, Ding Y, Luo WM, Bender S, Qian
CN, Kort E, Zhang ZF, VandenBeldt K, Duesbery NS, Resau JH, et al:
Inhibition of MAPK kinase signaling pathways suppressed renal cell
carcinoma growth and angiogenesis in vivo. Cancer Res. 68:81–88.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
During RL, Li W, Hao B, Koenig JM,
Stephens DS, Quinn CP and Southwick FS: Anthrax lethal toxin
paralyzes neutrophil actin-based motility. J Infect Dis.
192:837–845. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dudley DT, Pang L, Decker SJ, Bridges AJ
and Saltiel AR: A synthetic inhibitor of the mitogen-activated
protein kinase cascade. Proc Natl Acad Sci USA. 92:7686–7689. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Duesbery NS, Webb CP, Leppla SH, Gordon
VM, Klimpel KR, Copeland TD, Ahn NG, Oskarsson MK, Fukasawa K,
Paull KD, et al: Proteolytic inactivation of MAP-kinase-kinase by
anthrax lethal factor. Science. 280:734–737. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Abi-Habib RJ, Singh R, Leppla SH, Greene
JJ, Ding Y, Berghuis B, Duesbery NS and Frankel AE: Systemic
anthrax lethal toxin therapy produces regressions of subcutaneous
human melanoma tumors in athymic nude mice. Clin Cancer Res.
12:7437–7443. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chopra AP, Boone SA, Liang X and Duesbery
NS: Anthrax lethal factor proteolysis and inactivation of MAPK
kinase. J Biol Chem. 278:9402–9406. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ha SD, Ng D, Pelech SL and Kim SO:
Critical role of the phosphatidylinositol 3-kinase/Akt/glycogen
synthase kinase-3 signaling pathway in recovery from anthrax lethal
toxin-induced cell cycle arrest and MEK cleavage in macrophages. J
Biol Chem. 282:36230–36239. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hanna S and El-Sibai M: Signaling networks
of Rho GTPases in cell motility. Cell Signal. 25:1955–1961. 2013.
View Article : Google Scholar : PubMed/NCBI
|
